FOXOW FOXO TECHNOLOGIES INC.

Price Chart

Executive Summary

FOXO Technologies entered into a Strategic Technology License Agreement with its founder, Jon R. Sabes, and his entity LongevityFP Technologies, granting an exclusive worldwide license to FOXO's epigenetics IP in exchange for a 3% royalty capped at $1.3 million and a ten-year option for the licensee to acquire majority ownership of FOXO Labs. The agreement also includes mutual releases resolving prior matters between the parties.

Actionable Insight

Key Facts

• Exclusive worldwide license of FOXO's epigenetics IP to LongevityFP Technologies, controlled by founder Jon R. Sabes
• Royalty of 3% of net revenues from commercialization, capped at $1,300,000
• Ten-year exclusive option for LongevityFP to acquire majority ownership of FOXO Labs (Track A: 100% of FLI for 40% of LongevityFP equity; Track B: 60% of FLI for 40% retained by FOXO)
• FOXO retains ownership of FLI and the Licensed IP throughout the license period
• Agreement includes mutual releases resolving all prior matters between FOXO and Jon R. Sabes

Financial Impact

Royalty capped at $1.3 million; no upfront payment disclosed; potential equity upside from 40% stake in the resulting enterprise if option exercised

Risk Factors

• Royalty cap of $1.3 million limits total cash upside from the license
• Ten-year option creates long-term uncertainty over FOXO's ownership of FOXO Labs
• No upfront payment or minimum royalty guarantees

Market Snapshot

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status

Related Tickers